NCT06770699进行中（未招募）不适用
Prognostic Performance of Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma: a Prospective Multi-Center Observational Study
Jiangxi Provincial Cancer Hospital1 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2025年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 260
- 试验地点
- 1
- 主要终点
- Disease-free Survival
研究概览
简要总结
This study aims to conduct a prospective cohort study to validate the prognostic performance of Tertiary Lymphoid Structures (TLSs) as a predictive marker in pathological tissue sections for nasopharyngeal carcinoma (NPC). The TLS assessment framework established in this research has the potential to serve as a reference for personalized treatment strategies in NPC patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histopathological confirmed diagnosis of nasopharyngeal carcinoma (NPC).
- •No evidence of distant metastasis at initial treatment, with staging classified as II-III (AJCC 9th edition).
- •Patients aged 18-75 with a Karnofsky Performance Status (KPS) score ≥
- •Organ Function: Adequate organ function meeting the following criteria:
- •Hematology:
- •White blood cell count > 3.0 × 10⁹/L. Absolute neutrophil count (ANC) > 1.5 × 10⁹/L. Hemoglobin (Hb) > 90 g/L. Platelet count > 100 × 10⁹/L. Albumin ≥ 3 g/dL.
- •>Liver Function: Bilirubin ≤ 1.5 × the upper limit of normal (ULN); patients with Gilbert's syndrome may enroll if serum bilirubin ≤ 3 × ULN.
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN; for patients with liver metastasis, AST/ALT ≤ 5 × ULN.
- •Alkaline phosphatase (ALP) ≤ 3 × ULN; for patients with liver or bone metastasis, ALP ≤ 5 × ULN.
- •>Coagulation Function: International normalized ratio (INR), prothrombin time (PT), or activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- •>Renal Function: Serum creatinine ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL/min as calculated by the Cockcroft-Gault formula (see Appendix 8).
- •Patients willing and able to comply with visit schedules, treatment plans, laboratory tests, and other study procedures.
- •Willing to adhere to study arrangements and refrain from participating in any other clinical trials related to drugs or medical devices during the study period.
- •Signed a formal informed consent form, indicating that they understand and agree to participate in the study in compliance with hospital policies.
- •Sufficient tumor tissue stored in paraffin blocks, suitable for scientific research purposes.
排除标准
- •Patients with concurrent malignant tumors other than nasopharyngeal carcinoma.
- •Patients with a history of severe immediate allergic reactions to any drug used in this study.
- •Patients who lack legal capacity or have limited legal capacity.
- •Patients with a history of drug or alcohol abuse, or with physical or mental disorders, who, in the investigator's opinion, are unable to fully understand or comply with the study's procedures and potential complications.
- •Patients with other serious acute or chronic medical conditions, laboratory abnormalities, or mental disorders that may increase the risk of treatment-related adverse events, interfere with the interpretation of study results, or make them unsuitable for participation in the study, as determined by the investigator. These include, but are not limited to:
- •Autoimmune colitis, inflammatory bowel disease, noninfectious pneumonitis, pulmonary fibrosis;
- •Mental disorders such as dementia, epilepsy, or recent (within the past year) or active suicidal ideation or behavior.
- •Patients with a prior diagnosis of immunodeficiency or known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related diseases.
- •Pregnant or breastfeeding women, and male or female patients of childbearing potential who are unwilling or unable to use effective contraception throughout the study period and for at least one year after completing the treatment regimen.
结局指标
主要结局
Disease-free Survival
时间窗: 3 Years
DFS is defined as the time from the date of enrollment to the first occurrence of either disease progression (as confirmed by imaging or clinical evaluation) or death from any cause, whichever occurs first. For patients without these events, DFS is censored at the time of the last follow-up.
次要结局
- Overall Survival(3 Years)
- Locoregional Recurrenc-free Survival(3 Years)
- Distant Metastasis-Free Survival(3 Years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06241066Tianjin Medical University Cancer Institute and Hospital359
已完成
不适用
Heterogeneity of Tertiary Lymphoid Structures Predicts Distinct Malignancy and Immune Microenvironment in Prostate Cancer: a Retrospective Cohort StudyProstate CancerNCT06484127Fudan University200
已完成
不适用
Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary SyndromesAcute Coronary SyndromesNCT02117037Assistance Publique Hopitaux De Marseille180
尚未招募
不适用
The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancerthe Prognostic Value of Pre-treatment NLR in Patients With Locally Advenced Rectal Cancer and Post-treatmentNCT05673343Assiut University100
Unknown
不适用
Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.ProgressionLymphocyte DisorderMonocytosisLocal DiseaseRenal Cell CarcinomaNCT04213664Corporacion Parc Tauli4,666